Crescent Biopharma Stock (NASDAQ:CBIO)
Previous Close
$12.65
52W Range
$8.72 - $29.00
50D Avg
$11.53
200D Avg
$14.06
Market Cap
$344.18M
Avg Vol (3M)
$197.90K
Beta
1.34
Div Yield
-
CBIO Company Profile
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.